Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 940 of 5804
-
Stem cell hope for Parkinson's: expanded access trial offers treatment to 11 patients
Disease control NO_LONGER_AVAILABLEThis expanded access protocol is part of IND 027396 to evaluate efficacy and safety of multiple intravenous administrations of autologous HB-adMSCs for the treatment of Parkinson's disease for up to 11 patients who passed pre-screening, completed screening, and were not randomize…
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New bladder cancer device offered to patients with no other options
Disease control APPROVED_FOR_MARKETINGThe purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New Virus-Based therapy offered to bladder cancer patients who failed standard care
Disease control AVAILABLEThis is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.
Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo offered to GIST patients with no other options
Disease control AVAILABLEThe purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Last-Resort drug linvoseltamab offered to myeloma patients with no other options
Disease control APPROVED_FOR_MARKETINGProvide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Last-Resort cancer therapy made available to patients with no other options
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Last-Resort drug teclistamab made available for desperate myeloma patients
Disease control NO_LONGER_AVAILABLETeclistamab pre-approval access in relapsed or refractory multiple myeloma.
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug hope for Hard-to-Treat blood cancer
Disease control NO_LONGER_AVAILABLEThe purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Peanut allergy patch offers hope for kids
Disease control AVAILABLEThis is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
Sponsor: DBV Technologies • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Desperate cancer patients get early access to promising drug combo
Disease control AVAILABLEThis is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational …
Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a heart stent fix dangerous artery bulges in the neck?
Disease control TEMPORARILY_NOT_AVAILABLEThe purpose of this study is to evaluate the clinical use of the PK Papyrus Coronary Stent Graft System, a Humanitarian Use Device (HUD) approved by the FDA under a Humanitarian Device Exemption.
Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental leukemia drug made available for patients who have no other options
Disease control AVAILABLERequests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with KMT2A rearrangements, or frontline AML patients with NPM1 m…
Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental drug opens door for rare sarcoma patients with no options left
Disease control NO_LONGER_AVAILABLEA multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control NO_LONGER_AVAILABLEPatients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without cli…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental Immune-Boosting drug now available for bone cancer patients
Disease control AVAILABLEThis expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white b…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Eczema breakthrough: bacteria removal may reduce skin flares
Disease control Not yet recruitingOur hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
Phase: PHASE4 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can mindfulness stop psychosis before it starts?
Prevention Not yet recruitingThe main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment. The secondary objectives were to study the efficacy…
Phase: NA • Sponsor: Centre Psychothérapique de Nancy • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
Symptom relief Not yet recruitingFor the majority of cancer patients, radiotherapy is a crucial component of their treatment process. However, many patients experience anxiety before or during radiotherapy. This anxiety may be related not only to the cancer diagnosis and its prognosis, but also to unfamiliar asp…
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
New trial combines lifestyle changes and Weight-Loss drug to boost mental health
Disease control Not yet recruitingThis randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants wi…
Phase: NA • Sponsor: Ludwig-Maximilians - University of Munich • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can an AI camera on a catheter spot bladder cancer better than standard scopes?
Diagnosis Not yet recruitingThis is a single-arm study investigating the safety, feasibility and diagnostic performance of AI-assisted Uro-Cam catheter assessment that will be performed at the Prince of Wales Hospital. All patients who are referred to the urology outpatient clinic for hematuria workup, and …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC